e-learning
resources
Munich 2014
Wednesday, 10.09.2014
IPF and surroundings
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Retinoic acid-related orphan receptor-a (Rora) expression in patients with fibrotic interstitial pneumonias: A lung tissue study
E. Bibaki, A. Koutsopoulos, E. Tsitoura, E. Lagoudaki, S. Sarantoulaki, I. Lasithiotaki, N. Siafakas, G. Sourvinos, K. Antoniou (Heraklion, Greece)
Source:
International Congress 2014 – IPF and surroundings
Session:
IPF and surroundings
Session type:
Oral Presentation
Number:
4631
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Bibaki, A. Koutsopoulos, E. Tsitoura, E. Lagoudaki, S. Sarantoulaki, I. Lasithiotaki, N. Siafakas, G. Sourvinos, K. Antoniou (Heraklion, Greece). Retinoic acid-related orphan receptor-a (Rora) expression in patients with fibrotic interstitial pneumonias: A lung tissue study. Eur Respir J 2014; 44: Suppl. 58, 4631
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone
Source: International Congress 2014 – ILDs 1
Year: 2014
Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
IL-17+ cells immunoexpression in systemic sclerosis pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
"Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease"
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014
Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
The role of CCR2
+
CD4
+
T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment
Source: International Congress 2014 – ILDs 5
Year: 2014
Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
The clinical features of 13 patients with interstitial pneumonia with positive anti-glycyl-tRNA synthetase autoantibodies
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Airway centered interstitial fibrosis – An under-recognized type of idiopathic interstitial pneumonia
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Comparison of physiological impairment in ILD patients with and without diagnostic IPF features
Source: International Congress 2014 – ILDs 4
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept